Session » Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Pathogenesis, Animal Models and Genetics I: Therapeutic Interventions in Preclinical Animal Models of Scleroderma

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 820

CC-220: A Clinical Stage Immunomodulatory, Antifibrotic Drug For Systemic Sclerosis

Abstract Number: 821

Activation Of The Signal Transducer and Activator Of Transcription 3 By Transforming Growth Factor-Beta Promotes Fibroblast Activation and Tissue Fibrosis

Abstract Number: 822

Inhibition Of Casein Kinase II Reduces TGFβ Induced Fibroblast Activation and Ameliorates Experimental Fibrosis

Abstract Number: 823

Activation Of Liver X Receptors Inhibits Experimental Fibrosis By Interfering With Interleukin-6 Release From Macrophages

Abstract Number: 824

Bosentan Improves Vascular Abnormalities In Endothelial Cell-Specific Fli1 Knockout Mice By Increasing The DNA Binding Ability Of Fli1 – a Possible Mechanism Explaining The Effect Of Bosentan On Scleroderma Vasculopathy

Abstract Number: 825

Activating Transcription Factor 3 Regulates Canonical Transforming Growth Factor Beta Signaling In Experimental Fibrosis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.